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Abstract 
Although HLA-A3 and A11 have been reported to be ligands for KIR3DL2, evidence 
for any in vivo relevance of this interaction is still missing. To explore the functional 
importance of KIR3DL2 allelic variation, we analyzed the autoimmune disease 
pemphigus foliaceus, previously associated (lower risk) with activating KIR genes. 
KIR3DL2*001 was increased in patients (odds ratio (OR) = 2.04; p = 0.007). The risk 
was higher for the presence of both KIR3DL2*001 and HLA-A3 or A11 (OR = 3.76, p 
= 0.013), providing the first evidence that HLA-A3 and A11 may interact with KIR3DL2 
in vivo. The nonsynonymous single nucleotide polymorphism 1190T (rs3745902) was 
associated with protection (OR = 0.52, p = 0.018). This SNP results in a threonine-to-
methionine substitution. Individuals who have methionine in this position exhibit a 
lower percentage of KIR3DL2-positive natural killer (NK) cells and also lower intensity 
of KIR3DL2 on expressing natural killer cells; additionally, we show that the expression 
of KIR3DL2 is independent of other killer cell immunoglobulin-like receptors. 
Pemphigus foliaceus is a very unique complex disease strongly associated with 
immune-related genes. It is the only autoimmune disease known to be endemic, 
showing a strong correlation with environmental factors. Our data demonstrate that 
this relatively unknown autoimmune disease may facilitate understanding of the 
molecular mechanisms of KIR3DL2 ligand recognition. 
  
Introduction  
Killer cell immunoglobulin-like receptors (KIR) are expressed on the surface of natural 
killer (NK) cells and T cells, regulating the balance of activating and inhibitory signals 
[1]. These receptors are important for immune defense [2] and influence placentation 
during pregnancy [3]. KIR genes are located on chromosome 19q13.42 within the 
leukocyte receptor complex [4, 5]. 
They vary in number (presence/absence polymorphism) and in allelic polymorphism. 
Two gene content haplogroups have been reported: haplogroup A is characterized by 
many inhibitory genes and only one short-tailed activating gene (KIR2DS4) and is the 
most frequent in worldwide populations; haplogroup B shows high diversity of 
combinations of activating genes [6]. 
The framework KIR3DL2 is the longest KIR gene and spans 16256bp. It is also one of 
the most polymorphic KIR, with 86 described alleles [7]. The KIR3DL2 receptor 
comprises a 140 kDa dimeric molecule with three extracellular domains and a long 
intracellular tail, carrying two immune receptor tyrosine-based inhibitory motifs (ITIM) 
[8]. A long cytoplasmic tail is normally a hallmark of an inhibitory KIR; in contrast, 
activating KIR generally exhibit a short tail and associate with the immune receptor 
tyrosine-based activating motif (ITAM) containing signaling chain DAP12 [9, 10]. Thus, 
the nomenclature of this gene family is based on the number of extracellular domains 
and the size of the cytoplasmic tail; i.e., KIR3DL, three extracellular domains, long 
cytoplasmic tail [11]. 
In vitro studies have suggested that HLA-A3 and HLA-A11 are ligands of KIR3DL2 
[12] but these interactions appear to be weak, and highly peptide dependent. Indeed, 
to date only one peptide (and variants thereof) has been reported to support A3 and 
A11 recognition by KIR3DL2. Moreover, the in vivo significance of this interaction is 
unclear, especially in light of the finding that it does not lead to fully functional NK cells, 
in contrast to other inhibitory KIR/ligand pairs [13]. 
Although KIR polymorphism has been studied in many Brazilian populations [14–17], 
KIR3DL2 allele diversity has not been well characterized. In addition, there is little 
information about the role of KIR3DL2 allele polymorphism in diseases. Here, we 
analyzed the influence of KIR3DL2 alleles in an autoimmune disease cohort from 
Brazil. Pemphigus foliaceus (PF) is an autoimmune blistering disease of skin 
characterized by autoantibodies against desmoglein-1, a molecule important for cell 
adhesion [18]. Many genes, including HLA class II, have been reported to associate 
with differential susceptibility to PF [19–21]. Activating KIR genes are often associated 
with protection in infectious diseases and susceptibility to autoimmunity [22]. However, 
we recently showed that the presence of higher numbers and ratios of activating KIR 
genes protect from PF [23]. Pemphigus is endemic not only in Brazil, but also in 
Tunisia and Colombia and the disorder is sporadically seen around the world [24, 25]. 
PF is strongly related to environmental factors, possibly due to substances contained 
in the saliva of hematophagous insects or to infectious microorganisms that trigger the 
disease in susceptible individuals [26, 27]. This particularity of PF may explain why 
activating KIR have been associated with protection against the development of this 
disease. 
Allelic polymorphism of inhibitory KIR may result in functional differences, shifting the 
balance of inhibitory and activating signals in NK cells. KIR3DL2 is highly polymorphic 
and present in virtually all haplotypes [6, 28]. In addition to the fact that all individuals 
carry this gene, KIR3DL2 is highly expressed on NK cells [29]. KIR3DL2 is, therefore, 
a strong candidate for disease association studies as some KIR3DL2 allotypes could 
present differential inhibitory effects and affect susceptibility to diseases. Moreover, 
we previously demonstrated that activating KIR protect against PF [22]. Therefore, we 
hypothesized that stronger inhibitory KIR3DL2 allotypes could confer risk to PF. 
Here, we show that the allele KIR3DL2*001 and the single nucleotide polymorphism 
1190T (rs3745902) are associated with differential susceptibility to PF. We present 
genetic epidemiological support for an in vivo interaction between KIR3DL2 and 
HLAA3 and A11. Moreover we also show that the protective SNP 1190T marks 
KIR3DL2 differential expression levels suggesting the necessity for a threshold of 
inhibition for the development of PF. 
 
  
Results 
KIR3DL2*001 increases the susceptibility to PF 
We sequenced KIR3DL2 in patients and controls to test if the polymorphism of this 
gene plays a role in PF susceptibility. The frequencies of all detected alleles are shown 
in Supporting Information Table 1 and frequencies of the most common alleles are 
shown in Figure 1. The allele KIR3DL2*001 was associated with increased 
susceptibility to PF for both carrier and allele frequencies in Euro-descendants (odds 
ratio (OR) = 2.1, p = 0.015; OR =2.04, p = 0.007, respectively) (Table 1). A statistically 
nonsignificant increase of KIR3DL2*001 was seen in the Afro-descendants. The risk 
was increased for homozygotes KIR3DL2*001/001 (OR =3.83; p = 0.025), showing an 
additive effect. An increased risk as also seen when we analyzed presence of 
KIR3DL2*001 together with the presence of at least one copy of HLA-A3 or HLA-A11 
(OR = 3.76, p = 0.013; Table 2) 
Cytoplasmic variant 1190T protects from PF 
We next examined if individual SNPs, rather than alleles, were related to the 
susceptibility to PF. We excluded those SNPs present in low frequency or those that 
could be explained predominantly by a single allele. Three remaining SNPs were 
tested (Table 1), two in exon 3 (322G>A, rs654686; 337C>G, rs3188286) and one in 
exon 9 (1190C>T, rs3745902). The variant 1190T was negatively associated with PF 
in Euro-descendants (OR = 0.52, p = 0.018). No significant association for this variant 
was detected in Afrodescendants. As we reported before [23], the KIR relative effect 
in Euro-descendants is possibly higher than in Afro-descendants as a consequence 
of differences between ethnicities and the complexity of this disease. 
KIR3DL2 exhibits differential expression levels that correlate with 1190T 
Direct examination of KIR3DL2 expression levels on the NK cells of healthy donors 
revealed that the percentage of KIR3DL2+ NK cells was 2.6-fold higher in 1190C 
homozygotes as compared to donors homozygous for 1190T (Fig. 2). In addition to 
the percentage of positive NK cells, the 1190C>T SNP also correlated with differential 
expression levels of KIR3DL2; MFIs of KIR3DL2+ NK cells in 1190T homozygotes was 
1.4-fold lower than in 1190C homozygotes.  
1190T association is apparently independent of gene content haplotypes 
There is strong linkage disequilibrium between KIR3DL2 alleles and other KIR genes 
[30, 31]. Presence of haplotype A has been shown to be associated with increased 
susceptibility to PF [23]. Thus, we wondered whether haplotype A might exhibit overall 
higher KIR expression suggesting the linkage disequilibrium between KIR3DL2 and 
other genes in the haplotype might be, in fact, responsible for the correlation between 
1190T and differential expression levels. To answer this question, we analyzed 
KIR3DL1 expression in a subset of individuals in which KIR3DL2 expression was also 
measured. When we separated them based on amino acid position 376 caused by 
SNP 1190C>T genotypes, Thr/Thr and Thr/Met had a very similar percentage of 
KIR3DL1+ cells (p = 0.98) with similar levels of KIR3DL1 expression per cell (p = 0.50) 
(Fig. 3). We also did not see any correlation between KIR3DL1 and KIR3DL2 
expression among these individuals (Fig. 4). 
KIR3DL2*001 and 1190T possibly have distinct effects on PF susceptibility 
In order to test if KIR3DL2*001 and the variant 1190T have distinct effects on PF, we 
performed regression analysis with stepwise selection. In our model, we included the 
presence of variants KIR3DL2*001, 1190T, the concomitant presence of 
KIR3DL2*001 + ligand (A3 and/or A11) and the presence of homozygosity for 
haplotype A. The logistic regression analysis showed that both the presence of the 
variant 1190T (OR = 0.46; p = 0.02; log likelihood = 182.268) and concomitant 
presence of KIR3DL2*001 + ligand (OR = 3.2; p = 0.04 log likelihood = 177.833) 
retained in the model and explained the result. Similar result was found when we 
tested a model with all KIR3DL2 alleles and variants (not shown). 
  
Discussion 
KIR allelic polymorphism and its effect on disease outcome are not well characterized. 
KIR presence/absence polymorphism as well as combinations of KIR-HLA have been 
associated with several infectious and autoimmune diseases [22, 32]. In contrast to 
other autoimmune diseases in which KIR polymorphism has been associated, we have 
reported that activating KIR genes are protective against PF [23]. Here, we 
hypothesized that different KIR3DL2 allotypes could be stronger inhibitory than others, 
what could contribute to shift the balance of activating and inhibitory signals on the NK 
cell surface. Based on previous results, allotypes that show greater inhibition could 
potentially confer risk to PF. 
The HLA ligand specificity of KIR3DL2 remains unclear, although HLA-A*03 and A*11 
tetramers have been shown to bind to KIR3DL2 when folded with specific EBV 
peptides [12]. The fact that the susceptibility was increased when we analyzed 
carriage of KIR3DL2*001 together with the presence of at least one copy of HLA-A3 
or HLA-A11 (OR = 3.76, p = 0.013; Table 2) suggests that these HLA-A molecules 
interact with KIR3DL2 in vivo. Furthermore, the presence of ligands without the 
receptor was not associated with PF (Table 2). Together with previous data showing 
that activating KIR genes protect from PF, these results suggest that KIR3DL2*001 
may bind HLA-A3 and A11 in vivo and that this interaction stronger inhibitory receptor 
than other alleles. In addition, we tested the combination of KIR3DL2*001 with HLA-
Bw6 (previously associated with increased susceptibility to PF [23]) or other common 
class I alleles. No additive effect was seen for KIR3DL2*001 + Bw6 (OR = 1.89, p = 
0.02) or KIR3DL2*001 + other common HLA-A, B or C alleles (data not shown), 
corroborating the hypothesis that A3 and A11 may be functional ligands of KIR3DL2. 
In addition to A3 and A11, KIR3DL2 has also been shown to recognize B27, a group 
of HLA alleles closely associated with ankylosing spondylitis and B27-associated 
arthritides [33–35]. In our cohort, the frequency of HLA-B*27 is very low (f≤0.03 in 
patients and controls; Supporting Information Table 2), and therefore, not informative. 
HLA-A*03, in contrast, is one of the most common HLA-A alleles (Supporting 
Information Table 2) and combined with HLA-A*11, represents a ligand frequency 
higher than B*27 in the majority of worldwide populations, making these alleles the 
most likely primary KIR3DL2 in vivo ligands. 
The SNP 1190C>T was associated with differential susceptibility to PF (Table 1). This 
SNP causes an amino acid change (Thr376Met) in the long cytoplasmic tail. Although 
no major changes in mature protein are predicted for this replacement, the 
physicochemical properties of these two amino acids differ. Methionine is hydrophobic 
while threonine is polar due to the presence of a hydroxyl group. In the Grantham 
scale, which measures the physicochemical distance between all amino acid pairs and 
ranges from 5 to 215, the value for threonine and methionine is 81 [36]. Low values 
indicate conservative and high values indicate radical replacements. Even though it is 
an intermediate value, the frequency of amino acid replacements that show such 
difference is relatively low in mammalian proteins. Zhang [37], studying mammalian 
nuclear genes, estimated that only 17% of the transitions cause nonsynonymous 
substitutions that alter the polarity of the amino acids. 
Another more important characteristic that differs between these two amino acids is 
that threonine may be phosphorylated by protein kinases in eukaryotic cells. Although 
tyrosine phosphorylation is critical for both ITIM and ITAM function by facilitating the 
recruitment of the protein tyrosine phosphatases Src-homology domain containing 
phosphatase (SHP) 1 and 2, serine/threonine phosphorylation of KIR cytoplasmic 
domains can also play an important role in receptor expression and cycling, as has 
been reported for KIR3DL1 [38]. Importantly, Thr376 lies at position 1 relative to the 
tyrosine residue predicted to be critical within the KIR3DL2 ITIM. Moreover, 
experimental evidence supports a role for amino acids neighboring the ITIM tyrosine 
in controlling the ability of the receptor to interact with downstream molecules such as 
SHP-1. In particular, substitution at position 2 relative to the tyrosine in the ITIM can 
prevent its interaction with the protein phosphatases SHP-1 and SHP-2 [39]. Although 
to date position 1 has not been directly implicated in ITIM function, the Thr376Met it is 
certainly conceivable that this substitution may alter the receptor’s inhibitory function. 
In addition to the inhibitory capacity of the ITIM, this motif has also been recently 
implicated in the endocytosis of KIR in its unphosphorylated form due to interactions 
with the adaptor protein AP-2 [40]. Thus, modulation of this motif may also influence 
KIR3DL2 function via control of receptor internalization and/or cell surface expression 
levels. We tested this possibility by examining if the 1190C T SNP might correlate with 
KIR3DL2 expression (Fig. 2). Our data are the first to correlate differential expression 
of KIR3DL2 with a single nucleotide polymorphism and they reaffirm the functional 
significance of this SNP and corroborate our hypothesis. The proportion of cells 
expressing KIR3DL2 is lower in 1190T (Met376) homozygotes, in comparison to 
1190C (Thr376) homozygotes. This reduces the size of the NK cell subset that may 
be inhibited by KIR3DL2. In addition, the lower expression levels of KIR3DL2 on the 
cell surface of positive cells would be predicted to reduce their inhibitory potential. 
Thus, the NK cell population in 1190T individuals is biased toward lower inhibition in 
two ways, offering an attractive hypothesis as to why this SNP is negatively associated 
with PF. Our results also suggest that the differential expression levels of KIR3DL2 
are in fact independent of KIR3DL1 (Figs. 3 and 4). Therefore, we conclude that KIR 
haplotype gene content is not responsible for the differential expressions levels seen 
in KIR3DL2. 
Interestingly, the concomitant presence of the variant 1190T and the ligands HLA-A3 
and A11 has no effect on PF disease susceptibility (Table 2). Given the cytoplasmic 
location of this variant we would not expect it to affect binding affinities, rather our data 
show these KIR3DL2 alleles have lower expression levels perhaps reducing KIR3DL2 
expression to levels too low to effectively function as an inhibitory receptor. In contrast, 
the odds ratio of KIR3DL2*001 combined with presence of A3/A11 (OR = 3.76) is much 
stronger than the odds ratio of the presence of KIR3DL2*001 alone (OR = 2.04). 
Therefore, we see a stronger susceptibility effect when we combined KIR3DL2*001 + 
A3/A11. KIR3DL2*002 is the most frequent allele in our cohort and like KIR3DL2*001 
does not carry the variant 1190T. The fact the highly expressed allele KIR3DL2*002 
is not associated with PF (OR = 1.21; p =0.507; Table 1) tells us that there are likely 
two distinct factors contributing to susceptibility to PF: (i) differential inhibition 
conferred by KIR3DL2*001 compared to other highly expressed alleles, and (ii) the 
differential levels of KIR3DL2 expression associated with 1190T. 
Our regression analyzes corroborate this hypothesis and our data lead us to predict a 
model where PF-associated peptides presented in the context of A3 or A11 are 
recognized well by KIR3DL2 001 promoting disease. KIR3DL2 002, in contrast, may 
only recognize these ligands weakly, while the poorly expressed 1190T alleles fail to 
effectively inhibit NK cells regardless of their binding affinities. The reason why the 
molecules encoded by KIR3DL2*001 and KIR3DL2*002 would exhibit degrees of 
function is unknown. 
However, it is worth noting that these two molecules differ by only one amino acid 
(Glu137Asp) and that nearby residues (138 and 140) have been shown to be HLA 
contact residues in the related receptor KIR3DL1 [41]. Considering the similarity of 
KIR3DL2 and KIR3DL1, and assuming these receptors bind similarly to their 
respective ligands, Glu137Asp would be expected to be very close to HLA-binding 
region of KIR3DL2. Although Glu137Asp is a relatively conservative change between 
two negatively charged amino acids, its proximity to residues that may contact HLA 
could substantially change the ability of these KIR3DL2 allotypes to bind ligand. 
Alternatively, other characteristics of these allotypes may differ, such as alterations in 
receptor stability or folding. Formally, testing these hypotheses will require 
identification of peptides recognized by KIR3DL2 in PF patients and functional assays 
to verify the impact of the substitution Glu137Asp on KIR3DL2 binding. 
Conclusion 
KIR3DL2*001 is associated with increased susceptibility to PF in a gene dose and 
ligand-dependent manner, suggesting that it may be a potent inhibitor as compared to 
the other KIR3DL2 alleles. To our knowledge, no other studies have revealed apparent 
interactions between KIR3DL2 and HLA-A3 and A11 in vivo. Moreover, we find that 
KIR3DL2 exhibits differential expression levels that correlate with the SNP 1190C>T. 
Lower expression of KIR3DL2 protects against PF possibly due to an overall decrease 
in inhibitory signals within NK cells. This effect is independent of KIR3DL1 and 
apparently independent of gene content haplotypes. This is the first study showing 
that allele-specific KIR3DL2 differential expression levels are associated with disease. 
Additionally, the amino acid change caused by the SNP 1190C>T is also likely to 
interfere the receptor function by changing inhibitory signaling, hypothesis that need 
to be tested. Unfortunately, allelic information is still lacking for the majority of KIR 
studies and these data are crucial in comprehending the role that these genes play in 
other diseases. Our data demonstrate that even complex diseases such as pemphigus 
can yield invaluable knowledge regarding KIR-dependent mechanisms that regulate 
immune responses. 
 
  
 Materials and methods 
Samples 
A total of 156 patients and 141 controls without history of the disease were analyzed 
in this present study. Patients were contacted mainly at Hospital Adventista do 
Pênfigo, Campo Grande, MS, Brazil, a specialized hospital located at the endemic 
area. All individuals voluntarily agreed to participate and written informed consent was 
obtained from all participants. In accordance with Brazilian Federal laws, this study 
was approved by the Human Research Ethics Committee of the Federal University of 
Parana and the CONEP (Comissão Nacional de Ética em Pesquisa). Because 
different populations may differ in allele frequencies, the individuals were separated 
according to their predominant ancestry: Euro-descendants (Euro n = 104 patients 
and n = 90 controls) and Afro-descendants (Afro, n = 52 patients and n = 51 controls). 
This approach has been validated by previous population genetic studies from our 
group, which showed that the distribution of alleles known to be restricted to 
populations autochthonous from one continent follows a gradient among the 
population strata, as expected if the classification discriminated the strata according 
to relative contributions of the ancestral populations [42, 43]. Eurodescendants and 
Afro-descendants were also analyzed as a single population sample when the 
frequencies between them did not differ statistically; total sample may give us a better 
representation of the whole population. 
KIR3DL2 and HLA genotyping 
All individuals were genotyped for presence of KIR3DL2 in a former study [23]. Here, 
we amplified exons 3, 4, 5, 7, 8, and 9 and also intron 7 using gene-specific primers 
and the products were sequenced using the Big Dye terminator kit (Applied 
Biosystems). Specific PCR-SSP primers were designed to solve the 002/010 or 
010/015, 001/007, or 006/010 ambiguities. All primer sequences are available on 
request. The HLA genotyping was performed using the LABType SSO reagent kits 
(One Lambda, USA). 
Statistical analyzes 
Tests of population differentiation were performed by analyzes of 2 × 2 contingency 
tables, calculating the exact p-value by the metropolis algorithm. The p-value of 0.05 
was adopted as the significance limit. The Mantel–Haenszel method [44] was applied 
for calculating the OR and the 95% confidence intervals. Logistic regression analyzes 
with stepwise selection were carried out by IBM SPSS Statistics software. 
Flow cytometry 
KIR3DL2 and KIR3DL1 expression was assessed on a cohort of healthy, 
predominantly Caucasian, donors. Whole blood was stained with anti-CD3, anti-CD56, 
and anti-KIR antibodies (anti3DL2 (DX31; L. Lanier, UCSF) and anti-3DL1 (DX9, BD 
Biosciences)). After red blood cell lysis, the cells were washed, fixed, and analyzed 
using a BD LSRII flow cytometer using Diva software. Data was analyzed using 
FlowJo analysis software. 
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Figure Legends 
Figure 1. Carrier frequencies for each KIR3DL2 allele in patients and controls. 
Sequencing-based genotyping was applied to determine the frequencies of KIR3DL2 
in patients and controls. Bars show the frequencies of each allele and only the most 
frequent alleles are shown. Euro: Euro-descendants (patients, n = 104; controls, n = 
90); Afro: Afro-descendants (patients, n = 52; controls, n = 51); Total: total sample 
(patients, n = 156; controls, n = 141); (C) or (T): presence of the variant 1190C or 
1190T (rs3745902). 
Figure 2. Position 376 (1190C>T) marks KIR3DL2 expression. KIR3DL2 expression 
was assessed on a cohort of healthy, predominantly Caucasian, donors (n = 16). (A) 
Percentage of KIR3DL2 (DX31) positive NK cells versus TT (n =12) and MM 
genotypes (n = 4) was determined by flow cytometry. Whole blood was stained with 
anti-CD3, anti-CD56, and anti-3DL2 (DX31; L. Lanier, UCSF). Each dot represents an 
individual and horizontal bars represent the mean. Mann–Whitney test was used to 
compare groups. Position 376 is codified by the SNP rs3745902; 1190T: methionine 
(M); 1190C: threonine (T). (B) KIR3DL2 (DX31) median fluorescence intensity versus 
genotypes TT (n = 12) and MM (n = 4) was determined by flow cytometry. Whole blood 
was stained with anti-CD3, anti-CD56, and anti-3DL2 (DX31; L. Lanier, UCSF). Each 
dot represents an individual and horizontal bars represent the mean. Mann– Whitney 
test was used to compare groups. Position 376 is codified by the SNP rs3745902; 
1190T: methionine (M); 1190C: threonine (T). (C– F) Gating strategy. (C) Forward and 
side scatter plot of peripheral blood mononuclear cells. The lymphocyte population is 
selected. (D) Natural killer (NK) cells are identified using CD56 and CD3 antibodies. 
NK-positive cells are selected as CD56-positive and CD3-negative cells. Anti-
KIR3DL2 (DX31) positive cells are identified with NK-positive cells in a donor with (E) 
low expression and (F) high expression. 
Figure 3. Position 376 (1190C>T) does not correlate with KIR3DL1 expression. 
KIR3DL1 expression was assessed on a cohort of healthy, predominantly Caucasian, 
donors (n = 37). Due to the linkage disequilibrium between KIR genes and alleles, we 
could not find a representative number of MM/3DL1+ individuals. (A) Percentage of 
KIR3DL1 (DX9) positive NK cells versus TT (n = 30) and TM (n = 7) genotypes was 
determined by flow cytometry. Whole blood was stained with anti-CD3, anti-CD56, and 
anti-3DL1 (DX9, BD Biosciences). Each dot represents an individual and horizontal 
bars represent the mean. Mann–Whitney test was used to compare groups. Position 
376 is codified by the SNP rs3745902; 1190T: methionine (M); 1190C: threonine (T). 
(B) KIR3DL1 (DX9) median fluorescence intensity versus genotypes TT (n = 30) and 
TM (n = 7) was determined by flow cytometry. Whole blood was stained with anti-CD3, 
anti-CD56, and anti-3DL1 (DX9, BD Biosciences). Each dot represents an individual 
and horizontal bars represent the mean. Mann–Whitney test was used to compare 
groups. Position 376 is codified by the SNP rs3745902; 1190T: methionine (M); 
1190C: threonine (T). 
Figure 4. KIR3DL2 expression does not correlate with KIR3DL1 expression. KIR3DL1 
and KIR3DL2 expression were assessed on a cohort of healthy, predominantly 
Caucasian, donors (n = 37). KIR3DL1 (DX9) versus KIR3DL2 (DX31) median 
fluorescence intensity was determined by flow cytometry. Whole blood was stained 
with anti-CD3, anti-CD56, and anti-KIR antibodies (anti-3DL2 (DX31; L. Lanier, UCSF) 
and anti-3DL1 (DX9, BD Biosciences)). Each dot represents an individual. KIR3DL1 
and KIR3DL2 expression were measured in the same individuals. 
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Patients 
 
F (%) Controls 
 
F (%) p OR 95% CI 
 
  P A  P A      
Allele frequencies 
001 Euro 46 160 22.3 22 156 12.4 0.007 2.04 1.17–3.54 
 
 Afro 29 75 27.9 18 81 18.2 0.070 1.74 0.89–3.39  
 Total 75 235 24.2 40 237 14.4 0.002 1.89 1.24–2.89  
Carrier frequencies 
001 Euro 39 65 37.5 20 70 22.2 0.015 2.10 1.11–3.97 
 
 Afro 24 28 46.2 17 34 33.3 0.129 1.71 0.77–3.81  
 Total 63 93 40.4 37 104 26.2 0.010 1.90 1.16–3.11  
Genotypes 
001/001 Total 12 144 7.7 3 138 2.1 0.025 3.83 1.06–13.87 
 
001/other Total 51 105 32.7 34 107 24.1 0.087 1.55 0.93–2.60  
SNPs 
322A Euro 40 64 38.5 45 45 50.0 0.071 0.63 0.35–1.11 
 
 Afro 27 25 51.9 24 27 47.1 0.308 0.70 0.35–1.38  
337G Euro 29 75 27.9 24 66 26.7 0.490 1.06 0.56–2.00  
 Afro 9 43 17.3 15 36 29.4 0.146 0.50 0.20–1.28  
1190T Euro 40 64 38.5 49 44 54.4 0.018 0.52 0.29–0.93  
 Afro 23 29 44.2 21 30 41.2 0.752 1.13 0.52–2.47  
 
Table 1. 3DL2*001 and the SNP 1190T are associated to pemphigus foliaceus 
P: presence; A: absent; F: frequency, p: p-value; OR: odds ratio, CI: confidence interval. 
For simplification, KIR3DL2*001 is represented as 001. Bold highlights the significant associations. 1190T is the variant of the SNP 
rs3745902; 1190T: methionine (M) in position Thr376Met. 
  
 Table 2. Association of KIR3DL2 variants and HLA-A ligands with pemphigus foliaceus 
HLA-A ligand: presence of A3 and/or A11; P: presence; A: absent; F: frequency; p: p-value; OR: odds ratio; CI: confidence interval. 
For simplification, KIR3DL2*001 is represented as 001. Bold highlights the significant association. 1190T is the variant of the SNP 
rs3745902; 1190T:methionine (M) in position Thr376Met. 
 
  
Patients 
 
F (%) Controls 
 
F (%) p OR 95% CI 
  P A  P A     
Carrier frequencies 
HLA-A ligand Euro 47 59 44.3 23 46 33.3 0.146 1.59 0.85–2.99 
 Afro 23 35 39.7 13 21 38.2 0.887 1.06 0.44–2.53 
 Total 70 94 42.7 36 67 35.0 0.210 1.36 0.83–2.31 
3DL2*001+ 
HLA-A ligand Euro 18 61 22.8 4 51 7.3 0.017 3.76 1.20–11.82 
 Afro 6 29 17.1 3 25 10.7 0.360 1.72 0.39–7.61 
 Total 24 90 21.1 7 76 8.4 0.016 2.89 1.18–7.09 
1190T+HLA-A ligand Euro 
Afro 
10 
5 
69 
30 
12.7 
14.3 
8 3 48 
25 
14.3 
10.7 
0.488 
0.569 
0.87 
1.19 
0.32–2.36 
0.26–5.44 
 Total 15 99 13.2 11 73 13.1 0.582 1.00 0.44–2.32 
Figure 1 
 
 
 
  
Figure 2 
 
 
 Figure 3 
 
 
 
 
 
 
 
 
 
 
  
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
